<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02673814</url>
  </required_header>
  <id_info>
    <org_study_id>PPHM 1501</org_study_id>
    <nct_id>NCT02673814</nct_id>
  </id_info>
  <brief_title>Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer</brief_title>
  <official_title>An Open-Label, Randomized, Phase II Trial of Durvalumab (MEDI4736) With or Without Bavituximab in Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peregrine Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peregrine Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this research study is to see whether adding bavituximab (an&#xD;
      investigational drug) to durvalumab will improve the results of the treatment for&#xD;
      non-small-cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (durvalumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/kg durvalumab alone every two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (bavituximab + durvalumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg/kg bavituximab weekly in combination with 10 mg/kg durvalumab every two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (bavituximab + durvalumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg/kg bavituximab in combination with 10 mg/kg durvalumab both every two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>durvalumab</intervention_name>
    <arm_group_label>Arm A (durvalumab)</arm_group_label>
    <arm_group_label>Arm B (bavituximab + durvalumab)</arm_group_label>
    <arm_group_label>Arm C (bavituximab + durvalumab)</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bavituximab</intervention_name>
    <arm_group_label>Arm B (bavituximab + durvalumab)</arm_group_label>
    <arm_group_label>Arm C (bavituximab + durvalumab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Written Informed Consent&#xD;
&#xD;
          -  Male or female at least 18 years of age&#xD;
&#xD;
          -  Histologically or cytologically documented NSCLC (Non-small-cell lung carcinoma) who&#xD;
             present with Stage IV disease (according to the American Joint Committee on Cancer&#xD;
             Staging Manual [7th edition]) or with recurrent disease or progressive disease&#xD;
             following multimodal therapy (radiation therapy, surgical resection, or definitive&#xD;
             chemoradiation therapy for locally advanced disease)&#xD;
&#xD;
          -  Disease recurrence or progression during or after one prior platinum-based doublet&#xD;
             chemotherapy treatment for advanced or metastatic disease&#xD;
&#xD;
          -  Measurable disease on cross-sectional imaging per RECIST 1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status 0 or 1&#xD;
&#xD;
          -  Tumor tissue (archival or recent tumor biopsy) must be available for biomarker&#xD;
             evaluation&#xD;
&#xD;
          -  Adequate hematologic function (absolute neutrophil count ≥1500 cells/µL; hemoglobin ≥9&#xD;
             g/dL; platelets ≥100,000/µL).&#xD;
&#xD;
          -  Serum creatinine CL&gt;40 mL/min by the Cockcroft-Gault formula or by 24-hour urine&#xD;
             collection for determination of creatinine clearance&#xD;
&#xD;
          -  Adequate hepatic function (serum bilirubin ≤1.5 × ULN, serum albumin levels ≥3.0 g/dL,&#xD;
             alanine aminotransferase [ALT] ≤2.5 × ULN, and aspartate aminotransferase [AST] ≤2.5 ×&#xD;
             ULN)&#xD;
&#xD;
          -  Female patients must either be of nonreproductive potential or must have a negative&#xD;
             serum pregnancy test upon study entry&#xD;
&#xD;
          -  All patients of reproductive potential (ie, not surgically sterile or postmenopausal)&#xD;
             must agree to use a highly effective method of contraception during and 90 days after&#xD;
             the end of study treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of bleeding diathesis or coagulopathy (von Willebrand disease or&#xD;
             hemophilia)&#xD;
&#xD;
          -  Tumors invading large blood vessels that, in the opinion of the Investigator, put the&#xD;
             patient at risk for major hemorrhage&#xD;
&#xD;
          -  Clinically significant bleeding, such as gross hematuria, gastrointestinal bleeding,&#xD;
             and hemoptysis within the 6 months before screening, unless the cause has been&#xD;
             identified and adequately treated (eg, cystitis, ulcer)&#xD;
&#xD;
          -  Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, arterial&#xD;
             thrombosis) within 6 months before screening&#xD;
&#xD;
          -  Symptomatic coronary artery disease, cerebrovascular accident, transient ischemic&#xD;
             attack, myocardial infarction, arterial embolism, or unstable angina pectoris within 6&#xD;
             months prior to screening&#xD;
&#xD;
          -  QT interval using Fridericia's Correction (QTc) &gt; 500 ms&#xD;
&#xD;
          -  Symptomatic or clinically active brain metastases. Patients are eligible if brain&#xD;
             metastases are adequately treated. Patients must be either off corticosteroids or on a&#xD;
             stable or decreasing dose of ≤10 mg of daily prednisone (or equivalent).&#xD;
&#xD;
          -  Patients with symptomatic interstitial lung disease or inflammatory pneumonitis that&#xD;
             may interfere with the detection or management of suspected drug-related pulmonary&#xD;
             toxicity&#xD;
&#xD;
          -  Other active malignancy requiring concurrent intervention.&#xD;
&#xD;
          -  Acute toxicities attributed to prior anti-cancer therapy other than alopecia and&#xD;
             fatigue must have resolved to Grade 1 or baseline before administration of study drug&#xD;
&#xD;
          -  Active or prior documented autoimmune disease within the past 2 years&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 28 days before the first&#xD;
             dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or&#xD;
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of&#xD;
             prednisone, or an equivalent corticosteroid&#xD;
&#xD;
          -  Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative&#xD;
             colitis)&#xD;
&#xD;
          -  History of primary immunodeficiency&#xD;
&#xD;
          -  History of allogeneic organ transplant&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active&#xD;
             bleeding diatheses including any subject known to have evidence of acute or chronic&#xD;
             hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements or&#xD;
             compromise the ability of the patient to give written informed consent&#xD;
&#xD;
          -  Previous clinical diagnosis of tuberculosis&#xD;
&#xD;
          -  History of hypersensitivity to any of the excipients of bavituximab and durvalumab&#xD;
             including polysorbate-80-containing infusions.&#xD;
&#xD;
          -  Serious nonhealing wound, including wound healing by secondary intention&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to Cycle 1 Day 1 (C1D1)&#xD;
&#xD;
          -  Receipt of live attenuated vaccination within 30 days prior to study entry or within&#xD;
             30 days of receiving durvalumab&#xD;
&#xD;
          -  Prior therapy with a PD-1 or PD-L1 inhibitor, including durvalumab.&#xD;
&#xD;
          -  Prior therapy with bavituximab.&#xD;
&#xD;
          -  Investigational therapy within 28 days prior to C1D1.&#xD;
&#xD;
          -  Patient has a condition or is in a situation which, in the Investigator's opinion, may&#xD;
             put the patient at significant risk, may confound the study results, or may interfere&#xD;
             significantly with the patient's participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>February 2, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2016</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Bavituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

